ArticleResearch and practice in thrombosis and haemostasis2026
Tissue factor activity and 1-year mortality in patients with active cancer and acute ischemic stroke: findings from the SCAN study.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Stroke secondary to cancer-associated coagulopathy: a systematic review.Journal of neurology · 2026Pooled it
- Article
- Evaluation of 3 commercial assays for the measurement of tissue factor activity in human plasma.Research and practice in thrombosis and haemostasis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tissue factor (TF), the cellular receptor for plasma factor (F)VII/FVIIa and a key initiator of the extrinsic coagulation pathway, plays a central role in cancer-associated thrombosis. However, its prognostic significance in patients with active cancer (AC) and acute ischemic stroke (AIS) remains unclear. Objectives: This study evaluates the association between plasma TF activity and outcome in patients with AC and AIS. Methods: We analyzed data from the SCAN study, a prospective, multicenter, observational study conducted in Japan. Blood samples were obtained immediately after admission, prior to any stroke treatment. TF activity was measured using a chromogenic assay. Patients were dichotomized at the median TF activity. Kaplan-Meier survival and Cox proportional hazards models were used to assess 1-year mortality, and restricted cubic spline analysis was conducted to explore nonlinear associations between TF activity and mortality. Results: Among 135 patients with AC and AIS in the SCAN study database, 84 had available TF activity data. The median TF activity was 32.0 pM (IQR, 21.1-61.6 pM). Compared with the low TF activity group, the high TF activity group had a higher prevalence of distant metastasis (69% vs 40%; Conclusion: Elevated TF activity was independently associated with 1-year mortality in patients with AC and AIS. TF activity represents a potential prognostic biomarker in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.